Photo Credit: Eremeychuk
The following is a summary of “Association of validated patient reported outcome measures with patients’ self-reported disease status in axial spondyloarthritis,” published in the December 2024 issue of Rheumatology by Redeker et al.
Validated PROs in axial spondyloarthritis (axSpA) clinical trials may not fully reflect patients’ discomfort or disease status, leaving their real-world relevance unclear.
Researchers conducted a retrospective study to compare patients’ self-reported disease status with validated clinical trial measures during routine visits.
They analyzed data from 5 initial and last visits of patients with axSpA. ASDAS, BASDAI, ASAS20, ASAS40, and ASAS partial remission were compared with self-reported disease status and categorized into 4 severity levels. Mixed models assessed associations, revealing patterns in symptom burden.
The results showed 3,120 visits over 4.7 years from 557 patients with axSpA. Very good or mild status was reported in 98.7% and 90.9% of visits with inactive or low ASDAS, compared to 67.9% and 39.3% with high or very high ASDAS. Severe or very severe status occurred in 15.1% with ASAS20, 7.2% with ASAS40, and 0.6% with ASAS partial remission, compared to 26.0%, 25.1%, and 30.1% without these achievements.
They found that ASDAS and BASDAI effectively captured patients self-reported disease status in most visits. Other clinical trial measures failed to reflect self-reported status in a significant number of visits.
Source: academic.oup.com/rheumatology/advance-article-abstract/doi/10.1093/rheumatology/keae648/7917340
